Articles tagged with Osteoporosis
Professor Ego Seeman received the IOF Medal of Achievement for his outstanding scientific contributions to osteoporosis research. The award recognizes individuals who have significantly advanced the field of osteoporosis through their original and outstanding work.
Researchers at McGill University Health Centre discover a new pathway that controls bone remodelling with interferon gamma. Interferon gamma may become an efficient drug-target for treating osteoporosis.
Researchers at Rice University have discovered a genetic mutation in rats that links to cardiovascular disease, osteoporosis, and potentially Alzheimer's disease. The study found that the mutation also increases susceptibility to arterial calcification.
A new study published in JAMA found that osteoporotic fractures can double or triple mortality rates for up to 5-10 years after the fracture. The risk is particularly high for hip fractures in women and men over 75, with a nearly threefold increase in mortality.
A new method for determining osteoporosis treatment targets has been developed using the WHO's fracture risk assessment tool, FRAX¹. This approach considers both fracture risk and cost-effectiveness to provide more accurate and targeted treatment.
Researchers found excellent agreement between CT colonography's bone density measurements and DEXA results, identifying osteoporotic bones in patients. CT colonography may be a cost-effective way to screen more people for osteoporosis without additional radiation.
Researchers at Columbia University discovered that gut serotonin plays a crucial role in bone formation, challenging the long-held belief that the skeleton controls bone growth. The study found that inhibiting serotonin release can increase bone mass and potentially treat osteoporosis.
Medicare's funding cut for dual-energy X-ray absorptiometry (DXA) may discontinue critical health services for osteoporosis patients. The test is essential for identifying those at risk and monitoring bone health, potentially leading to increased fractures and costs.
A five-year study tracked over 625,000 patients in Southern California to find that a healthy bones program reduced hip fracture rates by an average of 37.2%, with some reductions reaching as high as 50%. Implementing initiatives such as bone density tests and anti-osteoporosis medications led to significant improvements.
A study at the University of Alabama at Birmingham has identified a crucial co-receptor in parathyroid hormone signaling that selectively stimulates bone formation. This finding could lead to new osteoporosis drugs and better bone-building therapies by targeting specific cell receptors responsible for calcium uptake from the blood.
The International Osteoporosis Foundation backs the National Osteoporosis Society in criticizing NICE guidance on osteoporosis prevention and treatment. Key concerns include women's access to effective treatments, exclusion of high-risk men, and lack of incorporation of the WHO-supported Fracture Risk Assessment Tool.
Common osteoporosis medications bisphosphonates may cause irregular heartbeats and serious atrial fibrillation in patients. The risk is significant, with up to two times more likelihood of serious AF compared to placebo, highlighting the need for caution when prescribing these medications.
Researchers found that heart failure patients have a fourfold higher risk of fracture and six times the risk of hip fracture compared to other heart patients. Heart failure and osteoporosis share common risk factors such as older age, female sex, smoking, and type-2 diabetes.
Research from the Norwegian Institute of Public Health reveals that low weight among middle-aged men increases the risk of osteoporosis and fracture. Conversely, stable weight is recommended for optimal bone health. The study found that weight loss, rather than gain, was linked to increased osteoporosis risk.
A Phase IIB study demonstrated dose-dependent increases in bone mineral density (BMD) at the total hip, lumbar spine, and femoral neck fracture sites in postmenopausal women with low BMD. Odanacatib selectively inhibits cathepsin K, a key enzyme in osteoclastic bone resorption.
The American College of Physicians (ACP) issues a guideline for the drug treatment of osteoporosis in men and women, recommending bisphosphonates as a first-line therapy. The guideline emphasizes individualized treatment decisions based on risks and benefits.
A retrospective analysis of 30,000 female Medicare patients found that osteoporosis fractures resulted in $15,522 per person in medical expenses over three years. The study also highlighted the need for osteoporosis prevention and treatment to mitigate fracture-related costs.
A study reveals that less than half of European osteoporosis patients take both calcium and vitamin D supplements with their treatment. The majority claim to miss doses due to lack of understanding or inadequate physician guidance. Improved patient education is crucial to maximize the benefits of combination therapy.
Researchers have discovered a potential new drug that 'opens the taps' for hormone release, potentially stimulating new bone growth. The approach involves stimulating parathyroids, tiny glands controlling PTH hormone, which could lead to increased calcium levels and bone formation.
USC School of Dentistry researchers found that aspirin can inhibit bone resorption and promote osteoblast formation in mice with osteoporosis. The study's findings suggest that aspirin may be a potential alternative to current treatments for osteoporosis, which affect both men and women.
The ETH Zurich and IBM team developed a breakthrough method that combines density measurements with large-scale mechanical analysis of the inner-bone microstructure. This allows clinicians to detect osteoporotic damage more precisely and adjust surgical plates accordingly.
Researchers have identified a short-acting protein GILZ that may disrupt the fat production pathway, leading to increased bone formation and decreased fat accumulation. Dr. Xingming Shi believes sustained GILZ action could be used to develop targeted therapies for osteoporosis and obesity.
A new study suggests that an ultrasound exam of the heel may be able to predict if a woman is at heightened risk for fractures due to osteoporosis. The research found that women who were considered higher risk had a significantly lower bone strength, increasing their fracture risk.
The Canadian Multicentre Osteoporosis Study (CaMos) reveals that for women, menopause marks a critical period of decreased bone mineral density, with an average loss of 6.8% over 5 years in the hip. In men, BMD decreases more gradually, starting earlier around age 40, with a second period of decline after age 70.
A new University of Illinois study found that a higher-protein diet with lean meats and low-fat dairy can lead to significant weight loss without compromising bone health. The research, published in the Journal of Nutrition, showed that participants who followed this type of diet experienced stable or even increased bone density.
The new Clinician's Guide incorporates the World Health Organization's absolute fracture prediction algorithm (FRAX), increasing the identification of patients at risk for osteoporosis. The guide now applies to men over 50 and post-menopausal non-Caucasian women, including African-Americans, Asians, and Latinas.
A global study found significant differences in the standard of care for osteoporosis across Europe, North America, and Australia. Women in Europe reported lower use of bone-saving drugs and fewer bone density tests than those in other regions, highlighting the need for improved regional comparisons.
Collaboration between physicians and dentists is essential for improving the early detection and treatment of patients with osteoporosis. Oral health maintenance plays a vital role in managing osteoporosis, and healthcare professionals should discuss patient care decisions with the physician.
The American College of Physicians has released a new clinical practice guideline on screening for osteoporosis in men. Osteoporosis is expected to affect nearly 50% more men over the next 15 years due to increasing rates among older adults.
The International Osteoporosis Foundation is urging EU countries to continue seeking government recognition and action to address the growing burden of osteoporosis. Despite progress in management, important care gaps remain, including limited access to bone mineral density machines and evidence-based treatments.
A landmark observational study is tracking the management of osteoporosis in 60,000 postmenopausal women from around the world. The Global Longitudinal Registry of Osteoporosis in Women (GLOW) aims to improve diagnosis and treatment standards, with data collected over five years.
A study published in the Journal of the American Society Nephrology found that raloxifene increases bone mineral density and reduces vertebral fractures in postmenopausal women with mild to moderate chronic kidney disease. The medication is safe and effective for this patient population, reversing bone loss and fracture risk.
A recent study discovered that variants of the LRP5 gene are linked to a significant increase in fracture risk by up to 20 percent and lower levels of bone mineral density, particularly in the spine and hip. The research, conducted on a large-scale evidence base, suggests that genetic factors play a major role in determining bone health.
The International Osteoporosis Foundation (IOF) welcomes the ESCEO European guidance for the diagnosis and management of osteoporosis in postmenopausal women. The guidance provides a roadmap for implementing the new FRAX tool based on the WHO technical report, offering case-finding strategies supported by health economic data.
A recent study published in Osteoporosis International found that up to 50% of postmenopausal women with osteoporosis stop their treatment within a year due to side effects. The study showed that fractures have significant physical, psychological, and social implications on patients' quality of life.
Researchers at Baylor College of Medicine found that Notch stimulates early proliferation of osteoblastic cells responsible for bone formation. However, when Notch function is abolished in these cells, osteoporosis occurs due to an imbalance between bone formation and resorption.
A study of over 7,000 patients found that bisphosphonate therapy for osteoporosis has little to no effect on the risk of bone necrosis. However, clinicians face significant challenges in treating bone necrosis when it presents itself in patients.
Research finds gastric cancer patients post-gastrectomy have high prevalence of osteoporosis (38.3%) and vertebral deformities. Screening by Dual-energy X-ray absorptiometry is recommended for those over 60 or with anemia/back pain.
Researchers at Texas A&M AgriLife's Vegetable and Fruit Improvement Center developed a special carrot to increase calcium absorption in humans. The study found a two-fold increase in calcium intake, which can help prevent diseases like osteoporosis.
A specially developed carrot has been produced to help people absorb more calcium, with a net increase in calcium absorption found in humans who ate the carrot. Adding this carrot to the diet can help prevent diseases like osteoporosis.
Researchers found that oral osteoporosis medications appear to reduce the risk of jaw degradation in patients. The study analyzed medical claims data from over 714,000 individuals and showed a protective association between oral bisphosphonates and adverse bone outcomes.
A 15-year study found women with low bone mineral density and a previous vertebral fracture had a higher risk of new vertebral fractures compared to those with normal bone density and no previous fracture. Women who experienced a new fracture were more likely to have a positive fracture history, weigh less, and report lower estrogen use.
A bone mineral density test given 15 years earlier predicted a woman's risk of developing fractures to her spine over time. More than half of the women with low BMD and existing spinal fractures developed new fractures over the 15-year study period, highlighting the importance of BMD testing for women over 50.
The International Osteoporosis Foundation (IOF) applauds the National Osteoporosis Society's (NOS) success in appealing the National Institute for Health and Clinical Excellence's (NICE) Guidance on osteoporotic fracture prevention. IOF calls for continued efforts to ensure clinically appropriate treatments are made available.
Researchers found a significant relationship between bone mineral density and fracture risk, regardless of trauma severity. Women who experienced high-trauma fractures were at increased risk for future fractures.
A study found that high-trauma nonspine fractures in older women and men are associated with low bone mineral density and an increased risk of a subsequent fracture. The researchers analyzed data from two U.S. studies and found that low bone mineral density was strongly associated with high-trauma nonspine fractures.
Geisinger's rheumatology department redesigned osteoporosis and rheumatoid arthritis care by simplifying the ordering process for bone density scans. As a result, 88% of patients received the scan, compared to 18% previously, with quadrupling the number of patients who underwent testing.
Researchers, led by Liyun Wang, aim to shed light on how osteocytes sense external stimuli and communicate with surface cells. This study may lead to effective drug therapies for treating debilitating bone diseases.
A new study found that Forteo significantly increased bone density measurements, particularly in the lumbar spine and hip, compared to Fosamax. The findings suggest Forteo may be a valuable treatment option for secondary osteoporosis caused by glucocorticoid use.
A Kaiser Permanente study found that electronic medical records and outreach programs significantly improved osteoporosis diagnosis and management in older women. The study, which analyzed data from 3,588 women aged 67 and older, showed a significant increase in bone density screening and osteoporosis medication after a fracture.
A new study from the University of Missouri-Columbia found that men engaging in predominantly low-impact forms of exercise have an increased incidence of osteopenia, a condition resulting in two times the risk of bone fracture. Regular weight-bearing activities can mitigate this risk and maintain healthy bones.
Researchers at Hebrew SeniorLife's Institute for Aging Research have examined nearly 100,000 genetic markers to determine which genes are responsible for osteoporosis and longevity. The studies found associations between specific genetic variants and traits such as bone mineral density and age at death.
Researchers found that universal bone densitometry followed by oral bisphosphonate therapy may be cost-effective for certain older men with or without prior fractures. The study suggested that this strategy could reduce the absolute 10-year incidence of clinical fractures among older men with a prior fracture.
A study by Dr. Michael Holick reveals that vitamin D deficiency is common and problematic, increasing the risk of chronic diseases such as osteopenia, osteoporosis, and certain cancers. The author suggests increasing recommended Adequate Intakes for vitamin D to 800-1000 IU/d.
Researchers found that COPD patients exhibit greater arterial stiffness, especially those with osteoporosis. This early sign of aging may contribute to the increased risk of cardiovascular disease in these patients.
New research reveals that active estrogen metabolites are a strong predictor of bone mineral density in men. Higher levels of these hormones tend to result in higher bone density, while lower levels increase the risk of osteoporosis.
A Phase III clinical study involving over 7,700 women found that Reclast reduced the frequency of all types of osteoporotic bone fractures by 70%, including a significant reduction in spine fractures. Bone mineral density also increased significantly in women on Reclast compared to placebo.
A new study has found that a once-a-year treatment for osteoporosis can be as effective as monthly or weekly regimens at reducing bone fractures. The treatment, zoledronic acid, was shown to reduce the risk of spinal fractures by 70% and hip fractures by 40% over three years.
A study of 372 men with prostate cancer found that 49% had osteoporosis, with those receiving hormone therapy and having undergone radical prostatectomy being at highest risk. The authors suggest that daily calcium intake could be used as a prognostic factor for osteoporosis in these patients.
A retrospective analysis found patients taking risedronate (Actonel) had a lower incidence of hip fractures compared to those taking alendronate. The REAL study used a health service utilization database and provided valuable insights into the clinical effectiveness of these osteoporosis treatments.